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Advances in cardiovascular research have identified oxidative stress as an important pathophysiological pathway in the development and
progression of heart failure. Oxidative stress is defined as the imbalance between the production of reactive oxygen species (ROS) and
the endogenous antioxidant defence system. Under physiological conditions, small quantities of ROS are produced intracellularly, which
function in cell signalling, and can be readily reduced by the antioxidant defence system. However, under pathophysiological conditions,
the production of ROS exceeds the buffering capacity of the antioxidant defence system, resulting in cell damage and death. Over the last
decades several studies have tried to target oxidative stress with the aim to improve outcome in patients with heart failure, with very limited
success. The reasons as to why these studies failed to demonstrate any beneficial effects remain unclear. However, one plausible explanation
might be that currently employed strategies, which target oxidative stress by exogenous inhibition of ROS production or supplementation
of exogenous antioxidants, are not effective enough, while bolstering the endogenous antioxidant capacity might be a far more potent
avenue for therapeutic intervention. In this review, we provide an overview of oxidative stress in the pathophysiology of heart failure and
the strategies utilized to date to target this pathway. We provide novel insights into modulation of endogenous antioxidants, which may lead
to novel therapeutic strategies to improve outcome in patients with heart failure.
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Introduction
Oxidative stress is involved in the development and progression
of clinical and experimental heart failure.1–4 Oxidative stress is
defined as a dysregulation between the production of reactive
oxygen species (ROS) and the endogenous antioxidant defence
mechanisms, the so called ‘redox state’. When present in low
concentrations, ROS plays a critical function in cell homeostasis.
However, excess ROS causes cellular dysfunction, protein and lipid
peroxidation, DNA damage, and eventually leads to irreversible
cell damage and death. This is also evident in the heart where
high sensitive troponin assays have demonstrated an increase in
troponin release during heart failure progression, suggesting a
gradual loss in cardiomyocytes.5
In the heart, an overabundance of ROS can lead to the develop-
ment and progression of maladaptive myocardial remodelling and
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.. heart failure (Figure 1). ROS directly impairs the electrophysiology
and the contractile machinery of cardiomyocytes by modifying pro-
teins central to excitation–contraction coupling, including L-type
calcium channels, sodium channels, potassium channels, and the
sodium–calcium exchanger.6 ROS can also alter the activity of the
sarcoplasmic reticulum Ca2+-adenosine triphosphatase (SERCA)
as well as reduce myofilament calcium sensitivity.6 Furthermore,
ROS induces an energy deficit by affecting the function of proteins
involved in energy metabolism.6 Finally, ROS has a pro-fibrotic func-
tion, by inducing cardiac fibroblast proliferation and matrix metal-
loproteinases resulting in extracellular remodelling.6
This review will summarize the current knowledge regard-
ing oxidative stress production and the antioxidant defence
mechanism in the heart, under physiological and pathophysi-
ological conditions. Furthermore, we recapitulate the current
knowledge, failures and successes, regarding the treatment of
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Figure 1 The effects of excessive oxidative stress on the myocardium. As a result of cardiac injury there is a severe accumulation of oxidative
stress (reactive oxygen species, ROS), which has several detrimental effects on the myocardium. 1. Cardiomyocyte electrophysiology is severely
affected by increased ROS. ROS reverses the function of the Na+/Ca2+ exchanger (NCX), leading to Ca2+ influx and Na+ efflux. ROS also
increases the influx of Ca2+ via the L-type calcium channels. Increased ROS also increases sarcKATP currents, leading to action potential duration
shortening, while also reducing KV currents and increasing late sodium currents leading to prolonged action potential durations. 2. Excessive
ROS promotes ryanodine receptor 2 (RyR2) activity and inhibits sarcoplasmic reticulum Ca2+-adenosine triphosphatase 2 (SERCA2) activity,
resulting in calcium overload and reduced myofilament calcium sensitivity, eventually leading to contractile dysfunction. 3. The mitochondria
react to ischaemic injury by producing increased levels of ROS, however the overabundance of ROS inversely results in further mitochondrial
and energy metabolism dysfunction. 4. The increase in ROS is also responsible for increased fibrosis resulting from an increase in tissue inhibitors
of metalloproteinases (TIMP) and reduction in matrix metalloproteinase (MMP) expression.
heart failure by targeting oxidative stress. Finally, we discuss
the future potential of targeting endogenous oxidative stress
defence mechanisms, to improve clinical outcome in patients with
heart failure.
Reactive oxygen species in heart
failure and antioxidant
mechanisms: a brief summary
Reactive oxygen species production in the heart is primarily
achieved by the mitochondria, NADPH oxidases, xanthine oxi-
dase, and uncoupled nitric oxide synthase (NOS) (Figure 2). Under
pathological conditions, the electron transport chain of the mito-
chondria induces the formation of large quantities of superoxide.
This increase has been shown to contribute to cardiomyocyte
damage and larger myocardial injury after an acute myocardial
infarction.7,8 ROS production is also enhanced due to an increased
expression and activity of NADPH oxidase, resulting from sev-
eral pathological stimuli, including mechanical stretch, angiotensin
II, endothelin-1, and tumour necrosis factor (TNF)-𝛼.9–11 Sim-
ilarly, xanthine oxidase expression and activity is also increased
in the failing heart, again leading to an increased production




































.. uncoupled and structurally unstable leading to an increased gen-
eration of ROS. In mice, increased generation of ROS leads to
left ventricular (LV) dilatation, contractile dysfunction, and LV
remodelling.12
Besides the drastic increase in oxidative stress production,
heart failure is also characterized by an exhaustion of the innate
antioxidant defence mechanism. In cardiomyocytes, as in most
cell types, the major endogenous components of the antioxidant
defence mechanism responsible for the inactivation of ROS are
superoxide dismutase (SOD), catalase, glutathione peroxidase
(GPx), nicotinamide adenine dinucleotide (NAD+) and glutathione
(GSH) (Figure 2). Several studies have observed a significant
decrease in the activities of SOD, catalase, and GPx in animal
models for heart failure.13–15 Furthermore, mice lacking SOD
or GPx exposed to cardiac injury have demonstrated worse
outcomes when compared to their wild-type littermates.16–20
NAD+, together with its reduced dinucleotide NADH, are piv-
otal in driving oxidation–reduction reactions involved in energy
production.21,22 Besides its role in regulating cellular energy
metabolism, NAD+ is a precursor for the phosphorylated dinu-
cleotide pair NADP+/NADPH, which plays a major role in the
detoxification of ROS.21,22 In several murine models of heart failure,
a reduction in myocardial NAD+ levels has been observed.23–25
Interestingly, a recent study demonstrated that nicotinamide
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Oxidative stress production and scavenging in cardiomyocytes under physiological and pathophysiological conditions. (Top) Under
physiological conditions oxidative stress in the form of reactive oxygen species (ROS) is produced in small quantities by the mitochondrial
electron chain, NADPH oxidase (NOX), xanthine oxidase (XO), and nitric oxide synthase (NOS). Mitochondrial respiration converts oxygen
to water, resulting in the production of small quantities of superoxide (O2
-) as a by-product. The process starts with electrons derived from
NADH2 and FADH2 moving along the respiratory transport chain through a series of cytochrome-based complexes (I, III, and IV). These
complexes eventually transport electrons to molecular oxygen. The high free energy of the electrons is gradually extracted and converted into
adenosine triphosphate. NOX is a multimeric complex composed of a plasma membrane spanning cytochrome b558 (NOX2) and cytosolic
components (Rac1, p47phox, p67phox, p40phox). Under physiological conditions this complex is in a resting state, producing minimal O2
-, by
transferring an electron from NADPH to molecular oxygen. XO, which is a cytoplasmic enzyme that catalyzes the oxidation of hypoxanthine
and xanthine to uric acid using molecular oxygen as an electron receptor, produces O2
- and hydrogen peroxide (H2O2) in the process. NOS
oxidizes the NOS cofactor BH4 utilizing NADPH to generate nitric oxide and L-citrulline from L-arginine and oxygen. Superoxide dismutase
(SOD) initiates the detoxification of ROS, by scavenging O2
- and converting it to H2O2. Both catalase and glutathione peroxidase (GPx) further
detoxify the H2O2 to water and oxygen. GPx utilizes two glutathione (GSH) molecules as electron donors in the reduction of H2O2 to water,
producing oxidized glutathione (GSSG) in the process. Once GPx oxidizes GSH to GSSG, GSH reductase (GR) can reduce GSSG back to GSH
at the expense of NADPH, forming the GSH redox cycle. The ratio of GSH to GSSG largely determines the intracellular redox potential.
(Bottom) Under pathophysiological conditions, oxidative stress production is increased as a result of increased NOX and XO expression,
coupled to blockage of the mitochondrial electron chain and uncoupling of NOS. Furthermore, the expression and activity (dotted lines) of
SOD, catalase, and GPx are reduced. The levels of GSH are also reduced, while the levels of GSSG are increased. This severe increase in
oxidative stress eventually leads to hypertrophy, fibrosis, apoptosis, and contractile dysfunction in the myocardium.
mononucleotide adenylyl transferase (Nmnat), an enzyme respon-
sible for the production of NAD+, is significantly repressed in
both models of murine heart failure and in heart failure patients.26
This observation suggests that NAD+ reduction also occurs in
the human setting. Furthermore GSH, like NAD+, is another








.. the elimination of lipid peroxidation products.27 Interestingly, a
reduction in total GSH has been observed in animals post-cardiac
injury.28,29 Furthermore, depletion of GSH was highly correlated
with serum TNF-𝛼 levels.29 In LV tissue of end-stage dilated or
ischaemic cardiomyopathy patients, total GSH was decreased by
54% when compared to controls.28 In another study, serum GSH
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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levels highly correlated with the symptom severity in heart failure
patients.30
Lessons from previous oxidative
stress treatments in heart failure
Based on the observation that the redox state is in disarray dur-
ing heart failure,31 several experimental and clinical studies tar-
geted oxidative stress producers (i.e. NADPH oxidases, xanthine
oxidase, and uncoupled NOS) or scavengers [i.e. SOD, catalase,
exogenous antioxidant (vitamin E, or folic acid), and GPx] to treat
heart failure (Table 1).11,12,18,19,26,28,29,32–54
Pre-clinical animal models
for anti-oxidative stress therapies
Targeting oxidative stress in the pre-clinical setting has been exten-
sively studied and demonstrated highly promising results. These
experimental studies have focused on three distinct approaches
to target oxidative stress in heart failure: (i) inhibition of oxida-
tive stress producers, (ii) improving endogenous antioxidant capac-
ity, and (iii) improving antioxidant capacity by supplementation of
exogenous antioxidants.
Initial experimental animal studies focused on inhibiting oxidative
stress production by targeting NADPH oxidases, xanthine oxi-
dase, or NOS uncoupling. NADPH oxidase inhibition in mice lack-
ing the cytosolic NADPH oxidase component p47phox, protected
the heart from LV remodelling and dysfunction post-myocardial
infarction.32 Inhibition of xanthine oxidase, by means of oxypurinol
(rats) or allopurinol (dogs), protected the heart from LV remod-
elling, improved LV contractile function and myocardial efficiency
post-cardiac injury.33,34 The production of ROS by the uncoupling
of NOS has also been studied as a possible target for heart failure.
Mice, with a knock-out for NOS3, exposed to transverse aor-
tic constriction (TAC), demonstrated a reduction in fibrosis and
myocyte hypertrophy.12 Similarly, inhibiting NOS by means of BH4
(sapropterin) treatment also protected mice from TAC-induced
cardiac injury.12 These observations suggested that directly inhibit-
ing ROS producers, thereby reducing oxidative stress, can result in
improved survival and cardiac function following cardiac injury.
Besides targeting oxidative stress production, early experimental
studies demonstrated that increasing the endogenous antioxidant
capacity leads to improved cardiac function in rodent models for
heart failure. Specifically, these studies focused on the primary
antioxidant enzymes (SOD, catalase, and GPx) and antioxidants
(NAD+, GSH, vitamin E, and folic acid). Mice overexpressing
SOD when exposed to ischaemia/reperfusion injury were found to
have severely decreased levels of superoxide production, improved
contractile function, and a decrease in infarct size.35 Similarly,
mice with a cardiomyocyte specific overexpression of catalase
in a transgenic model for dilated cardiomyopathy were found to
have a significant reduction in adverse remodelling (i.e. myocyte
hypertrophy, myocyte apoptosis, and interstitial fibrosis) and the
progression of heart failure.36 Finally, mice with an overexpression



















































































.. have improved cardiac tissue survival and function, resulting from
an inhibition of LV remodelling.18,19
Following these positive results obtained by increasing
the endogenous expression of antioxidant enzymes, several
experimental studies tried to improve the endogenous antioxidant
capacity. Early studies focused on increasing the endogenous
levels of GSH, by the administration of N-acetylcysteine (NAC),
a precursor of GSH. NAC is readily absorbed into cells, where
it is converted into cysteine, the rate-limiting amino acid in the
synthesis of GSH. These studies demonstrated that NAC can
improve GSH levels, reduce oxidative stress, and improve cardiac
function in rat models of cardiac injury.28,29 To further address
the importance of the antioxidant capacity, several experimental
studies demonstrated that supplementation of vitamin E and
folic acid leads to improved cardiac function in models for heart
failure.37–40 Recently, a study has demonstrated that by increasing
the levels of NAD+, by supplementation of nicotinamide riboside
(NR), a precursor of NAD+, leads to improved cardiac function
and redox state in a murine heart failure model.26 These findings
suggest that by increasing the antioxidant capacity of the heart,
cardiomyocyte survival is improved, and the myocardium is better
able to cope with injury.
Clinical anti-oxidative stress therapies
Due to these highly promising results in animal models, several
studies have assessed the potential of anti-oxidative stress ther-
apies in the clinical setting. Similar to the animal studies, clinical
trials have taken three approaches to targeting oxidative stress in
heart failure patients: (i) inhibition of oxidative stress producers
(xanthine oxidase and NOS uncoupling), (ii) improving endogenous
antioxidant capacity (NAC), and (iii) improving antioxidant capacity
by supplementation of exogenous antioxidants (vitamin A, vitamin
C, vitamin E, and folic acid).
At present, the best studied therapy in patients with heart
failure is the inhibition of xanthine oxidase by the administration
of allopurinol or oxypurinol.11,41–47 The initial clinical trials were
small studies (n= 9–60) in patients with dilated cardiomyopathy
and chronic heart failure. These trials all demonstrated that
treatment with allopurinol or oxypurinol improved myocardial
function, peripheral vasodilatation capacity, blood flow, endothelial
dysfunction, reduced plasma B-type natriuretic peptide levels,
and increased LV ejection fraction.11,41,44–47 However, in a larger
randomized controlled trial in 405 patients with heart failure,
oxypurinol did not improve clinical outcome.42,43 The primary
endpoint of the study was a combined clinical endpoint that
classified the patient’s clinical status as improved, worsened, or
unchanged 24weeks after the initiation of the study. Compared
to the placebo group, patients demonstrated no improvement
in clinical status following oxypurinol treatment.42,43 Similarly,
inhibition of NOS uncoupling, by means of sapropterin treat-
ment, has also been studied in the clinical setting. Several small
clinical trials have been performed with oral sapropterin admin-
istration in patients (n= 18–49) with systemic or pulmonary
hypertension.48,55,56 However, these trials all failed to demonstrate
significant differences in nitric oxide synthesis, oxidative stress,
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Summary of pre-clinical and clinical trials using anti-oxidative stress treatments
Experimental
animal studies
Target Treatment Model Results Ref.




NADPH oxidase Cytosolic NADPH
oxidase component
p47phox knock-out
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Table 1 Continued
Clinical studies Target Treatment Patients Results Ref.






Chronic HF (n= 60) Improved LV ejection fraction 41










Chronic HF (n= 50) Reduced plasma BNP levels 44
Primary percutaneous
transluminal coronary
angioplasty in patients with
acute MI (n= 38)







blood flow locally and
systemically
46







No effect on vascular



























Reduced rate of non-fatal MI 52
Combined vitamin A, C,
E, and 𝛽-carotene







(50 studies, n= 294 478),
including coronary heart
disease, acute MI, unstable
angina, TIA, stroke, and
angiographically proved
coronary atherosclerosis





BNP, B-type natriuretic peptide; CHF, congestive heart failure; GPx, glutathione peroxidase; GSH, glutathione; HF, heart failure; LV, left ventricle; MI, myocardial infarction;
NAD+ , nicotinamide adenine dinucleotide; NOS, nitric oxide synthase; SOD, superoxide dismutase; ROS, reactive oxygen species; TIA, transient ischaemic attack; TNF, tumour
necrosis factor.
systemic haemodynamics, vascular redox state, or endothelial
function.
Following these disappointing results by inhibiting oxidative
stress production in patients, clinical studies went on to assess
the potential of increasing the antioxidant capacity in heart failure
patients. The majority of the trials performed to date have involved











. C, vitamin E, and folic acid). Initial studies found that the supple-
mentation of exogenous antioxidants leads to a reduction in car-
diovascular events, infarct sizes, and oxidative stress.52,53 However,
a recent meta-analysis of 50 randomized controlled trials studying
the effects of vitamin and antioxidant supplementation, including
294 478 participants, concluded that supplementation with exoge-
nous vitamins and antioxidants was not associated with reductions
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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in the risk of major cardiovascular diseases.54 More interestingly,
several clinical trials have demonstrated that improving the antiox-
idant capacity, by bolstering endogenous GSH levels, does show
some promise in heart failure patients. These trials demonstrated
that supplementation of NAC in patients resulted in a reduction in
oxidative stress, as measured by an increase in the GSH/oxidized
GSH (GSSG) ratio, infarct size and an improved cardiac function in
patients with heart failure and acute myocardial infarction.49–51,57
Why have clinical anti-oxidative stress therapies largely
failed?
Taken together, these findings suggested that although targeting
oxidative stress is theoretically logical, the majority of the strategies
currently employed in the clinical setting have failed to improve
patient prognosis. Furthermore, the exact reasons and mechanisms
as to why these studies have failed to produce the expected
beneficial effects, remain largely unknown. One reason could
be that in the experimental setting, the majority of the studies
utilized heart failure models to test the efficacy of anti-oxidative
stress treatments, while in the clinical setting anti-oxidative stress
treatments were primarily tested in patients with acute myocardial
infarction and not heart failure. Although it is well documented
that following myocardial infarction there is a surge in oxidative
stress,58 it maybe that at this stage anti-oxidative stress therapies
are not capable of limiting the production of oxidative stress.
Rather, these strategies may serve to improve outcome in heart
failure patients, where there is less oxidative stress production.
Another reason for this discrepancy could be that only specific
patient populations benefit from anti-oxidative stress treatments.
Or else the inadequate understanding of the mechanistic mode of
action of the administered antioxidant.
With regard to targeting oxidative stress production in human
heart failure, it has been speculated that these therapies may
be beneficial for a specific subset of patient. Oxypurinol has
been shown to improve heart failure symptoms in a specific sub-
set of patients with elevated uric acid, the product of xanthine
oxidase.43,59 Thus, identifying patients with increases in oxida-
tive stress production resulting from xanthine oxidase activity
may still benefit from this therapeutic approach. Several current
anti-oxidative stress therapies have also been found to result in
some off-target effects. Sapropterin administration was found to
result in an unexpected increase in oxidized BH4, BH2, a competi-
tive inhibitor of BH4 that promotes NOS uncoupling.
48,60 Similarly,
supplementation with 𝛼-tocopherol (vitamin E) has been shown to
drastically suppresses the levels of 𝛾-tocopherol (the more potent
antioxidant, found primarily in the diet), thereby possibly reducing
rather than increasing total antioxidant capacity.61
Although the findings of clinical trials aimed at reducing ROS
production and increasing exogenous antioxidants have been dis-
appointing, targeting oxidative stress, specifically the endogenous
antioxidant capacity, in heart failure should not be entirely disre-
garded. Noteworthy has been the observation that increasing the
antioxidant capacity, by bolstering endogenous GSH levels via NAC
supplementation, results in improved patient outcome, without



















































































.. therapies should focus on improving the endogenous antioxidant
capacity, rather than inhibiting oxidative stress production or sup-
plementation of exogenous antioxidants.
The future of oxidative stress as a
therapeutic target in heart failure
The major endogenous antioxidants in mammalian cells are NAD+
and GSH, the latter produced via the 𝛾-glutamyl cycle. NAD+ has
a multitude of cellular functions, and more recently it has become
evident that it plays an important role in the detoxification of
cellular ROS. Similarly, GSH protects cells against oxidative stress,
and both NAD+ and GSH levels have been shown to be associated
with heart failure in the experimental and clinical setting.23–30
Furthermore, supplementation of NAD+ or GSH precursors has
been found to improve cardiac function and redox state in models
for heart failure.26,28,29 Thus, we propose two approaches for
future anti-oxidative stress therapies in heart failure patients: (i)
increasing the endogenous antioxidant capacity, and (ii) increasing
the expression/activity of antioxidant producing enzymes.
Improving endogenous antioxidant
capacity in heart failure
Increasing the endogenous antioxidant capacity can be primarily
achieved by supplementation of precursors of the major cellular
antioxidants GSH and NAD+. The effectiveness and safety of this
approach has previously been demonstrated with the supplemen-
tation of NAC, a precursor of GSH, to heart failure patients and
acute myocardial infarction patients, resulting in improved patient
outcome.49–51,57 Thus, increasing the levels of endogenous antioxi-
dants seems to be a promising target for not only treating oxidative
stress in myocardial infarction, but also in heart failure patients.
Improving the endogenous levels of GSH can be achieved by
supplementation with GSH precursors which can be utilized
by the 𝛾-glutamyl cycle for de novo GSH synthesis (Figure 3).
Besides NAC, 𝛾-glutamylcysteine, another GSH precursor,
and 2-oxothiazolidine-4-carboxylate (OTC), an analogue of
5-oxproline, also seem to have the potential to increase
endogenous GSH levels. Both 𝛾-glutamylcysteine and OTC
increased GSH and reduced oxidative stress in experimental
and clinical studies.62–68 Similar to NAC, supplementation of
𝛾-glutamylcysteine increased the levels of GSH in patients with
cancer, with no adverse effects.62 OTC, which is converted to
cysteine by 5-oxoprolinase (OPLAH), increased GSH levels in the
experimental setting.63,64 Interestingly, early experimental studies
have shown that OTC improved cardiac function following cardiac
injury.65,67 Furthermore, in several clinical trials OTC treatment
had no adverse effects and increased GSH concentrations and
decreased oxidative stress in patients with acute respiratory
distress syndrome and HIV patients.67,68
Besides improving the endogenous GSH levels in heart failure,
another approach could be to increase the levels of endogenous
NAD+. NAD+ can be derived from several precursors, including
deamidated precursors, such as tryptophan, nicotinic acid, ami-
dated vitamin B3 nicotinamide and NR.21 The most promising of
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Drug therapies targeting endogenous glutathione (GSH) synthesis. GSH is synthesized from cysteine (the rate-limiting amino acid),
glutamate, and glycine by the 𝛾-glutamyl cycle. GSH is then utilized by GSH peroxidase (GPx) to reduce oxidative stress, and in the process
forming oxidized GSH (GSSG). GSSG is then reduced by action of GSH reductase (GR). Improving the 𝛾-glutamyl cycle’s ability to produce GSH
has been characterized as a treatment target in heart failure. N-acetylcysteine (NAC), 𝛾-glutamylcysteine, and 2-oxothiazolidine-4-carboxylate
(OTC, also known as pro-cysteine) are compounds which have demonstrated the capacity to increase the endogenous production of GSH.
OTC is converted to cysteine, by action of 5-oxoprolinase (OPLAH), to be used for de novo synthesis of GSH. Similarly, NAC is converted to
cysteine intracellularly, and used for GSH synthesis. 𝛾-Glutamylcysteine is utilized by the 𝛾-glutamyl cycle to form GSH, by addition of glycine.
GCL, glutamate cysteine ligase.
these precursors to date is NR, which is converted to NAD+
by NR kinase (Nmrk) and nicotinamide mononucleotide adenylyl
transferase (Nmnat). It has been recently demonstrated that sup-
plementation of NR in murine models for dilated cardiomyopathy
and pressure overload-induced heart failure, can restore NAD+
levels and preserve cardiac function.26
Although only few studies have focused on increasing the
endogenous antioxidant capacity in models for heart failure, the
results to date may be promising. Furthermore, the observation
that NAC supplementation in heart failure patients leads to
increased GSH levels suggests that this might be a potential strategy
for reducing the increase in oxidative stress resulting from cardiac
injury. Future studies should thus focus on further characterizing




















. (𝛾-glutamylcysteine and OTC) and NAD+ precursors (NR) on
heart failure patient outcome.
Targeting the endogenous production
of antioxidants in heart failure
Besides improving endogenous antioxidant capacity by administra-
tion of GSH and NAD+ precursors, another avenue for reducing
oxidative stress in heart failure is to improve the expression and/or
activity of the 𝛾-glutamyl cycle and NAD+ producers.
Recent experimental studies have demonstrated that several
components of the 𝛾-glutamyl cycle are strongly associated with
the development and progression of heart failure (including
𝛾-glutamylcysteine synthetase, GPx, and OPLAH). Furthermore,
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 4 Targeting 5-oxoprolinase (OPLAH) to reduce oxidative stress in heart failure. Following cardiac injury, OPLAH expression is
reduced, leading to the accumulation of 5-oxoproline. 5-Oxoproline then leads to drastic increase in oxidative stress (reactive oxygen species,
ROS). To help reduce the insult of 5-oxoproline to the injured myocardium, two strategies could be developed: (i) to pharmacologically improve
the remaining OPLAH’s ability to reduce 5-oxoproline, or (ii) to increase OPLAH expression by means of gene therapy. ADP, adenosine
diphosphate; ATP, adenosine triphosphate; GSH, glutathione.
modulation of these enzymes, by overexpression, has resulted
in cardioprotection.18,19,69,70 Of particular interest is OPLAH, a
cytoplasmic enzyme of the GSH cycle whose only function is the
conversion of 5-oxoproline, a degradation product of GSH, into
glutamate (Figure 4). Interestingly, studies have demonstrated that
excessive 5-oxoproline accumulation can lead to the induction of
intracellular oxidative stress.70–72 Therefore, OPLAH plays a piv-
otal role not only in the 𝛾-glutamyl cycle, by producing glutamate
for de novo GSH synthesis, but also as an antioxidant by scavenging
5-oxoproline.
OPLAH expression is suppressed in heart failure, both in the
experimental and clinical setting.70,73 In the murine setting, reduc-
tion in OPLAH increased plasma 5-oxoproline levels in cardiac
tissue and plasma, which coincided with an increase in oxidative
stress.70 Interestingly, elevated levels of plasma 5-oxoproline
in chronic heart failure patients were associated with higher
N-terminal pro-B-type natriuretic peptide, incidence of atrial
fibrillation, and all-cause mortality.70 In a recent study, OPLAH
overexpression in mice exposed to ischaemia/reperfusion injury
or permanent myocardial ischaemia improved cardiac function,
reduced infarct size and fibrosis, when compared to wild-type
littermates.70 Improved cardiac function in the OPLAH overex-
pression mice was coupled to reduced 5-oxoproline levels and
improved GSH/GSSG ratio post-cardiac injury.70 Thus, stimulating
the expression and/or activity of OPLAH could lead to novel
therapeutic strategies for patients with heart failure.
Similar to the 𝛾-glutamyl cycle genes, there are several NAD+
producers, most noteworthy is Nampt. Nampt has been shown










































.. setting.26 Furthermore, overexpression of Nampt in mice was
found to protect these animals against ischaemia/reperfusion injury
and isoproterenol-induced hypertrophy.23,24 Therefore, increasing
the expression and/or activity of Nampt might be a potential target
for the treatment of heart failure.
To date there are no known pharmacological agents (i.e. drugs
or small molecules) that have the capacity to induce OPLAH
activity. There are however several Nampt activators, although
limited information is currently available about these compounds
in patients.74,75 Future studies should therefore focus on (i) identi-
fying novel pharmacological agents that specifically target OPLAH,
and (ii) characterize Nampt activators in the clinical setting.
Similarly, the development of an OPLAH or Nampt gene therapy,
as recently described for SERCA2, could also serve as a viable
therapeutic strategy.76 Furthermore, besides OPLAH and Nampt,
other members of the 𝛾-glutamyl cycle and NAD+ producers
should also be screened for their potential use as therapeutic
targets in heart failure.
Conclusion
The role of oxidative stress in the onset and progression of
heart failure has been extensively studied. Pre-clinical studies
showed promising results with various anti-oxidative strategies,
but these beneficial effects did not translate into positive results
in clinical studies in patients with heart failure. This might be
caused by inadequate patient inclusion criteria or off target effects
of currently employed therapies. Therefore, we believe there is
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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still room for novel antioxidant approaches in heart failure. In
particular, targeting the endogenous antioxidant capacity might be
interesting new targets in the treatment of heart failure. Of interest
would be the development of medications capable of interacting
with the components of the 𝛾-glutamyl cycle or NAD+ production,
which may lead to novel treatment options for heart failure in the
future.
Conflict of interest: none declared.
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